

TABLE. 1

| Patient Group | Mean [sE-cadherin] in sputum supernatant (ng/ml) | Mean [sE-cadherin] in serum (ng/ml) | Mean [sE-cadherin] in urine (ng/ml) | Mean [IL-8] (mmol/L) | Mean [Creatinine] (mmol/L) | [Urine]/[Creatinine] ratio | Age of patient | Sex of patient | Medication taken by patient | Pack Years | FEV1 % pred |
|------------------------------|--|-------------------------------------|-------------------------------------|----------------------|----------------------------|----------------------------|----------------|----------------|-----------------------------|------------|-------------|
| COPD | 1 294 | 5082 | 1795 | 5049 | 8.1 | 222 | 59 | F | nil | 35 | 60 |
| COPD | 2 94 | 4728 | 1518 | 10661 | 1.3 | 1168 | 66 | M | salb, atro | 44 | 66.2 |
| COPD | 3 810 | 6239 | 1900 | 3218 | 4.7 | 404 | 48 | M | nil | 30 | 64.5 |
| COPD | 4 71 | 7297 | 255 | 3598 | 0.6 | 425 | 45 | M | nil | 30 | 75 |
| COPD | 5 830 | 5342 | 3066 | 548 | 17.5 | 175 | 47 | M | atro | 25 (ex) | 41 |
| COPD | 6 1749 | 6781 | 3603 | 4809 | 12.4 | 291 | 43 | M | nil | 30 | 69 |
| COPD | 7 179 | 5208 | 996 | 15397 | 3.2 | 311 | 45 | F | nil | 30 | 67.1 |
| COPD | 8 821 | 1761 | 5617 | 14056 | 10.9 | 515 | 54 | M | nil | 40 | 23 |
| COPD | 9 815 | 5198 | 2340 | 11147 | 2.8 | 836 | 56 | F | nil | 40 | 40.4 |
| COPD | 10 658 | 2736 | 5034 | 2954 | 12.3 | 409 | 65 | M | salb, atro | 30 (ex) | 54 |
| Mean values of Patient Group | 632 | 5037 | 2612 | 7144 | 7.4 | 476 | 53 | 7 M | - | 35 | 56 |

| Patient Group | Mean [sE-cadherin] in sputum supernatant (ng/ml) | Mean [sE-cadherin] in serum (ng/ml) | Mean [sE-cadherin] in urine (ng/ml) | Mean [IL-8] | Mean [Creatinine] (mmol/L) | [Urine]/[Creatinine] ratio | Age of patient | Sex of patient | Medication taken by patient | Pack Years | FEV1 % pred | |
|------------------------------|--|-------------------------------------|-------------------------------------|-------------|----------------------------|----------------------------|----------------|----------------|-----------------------------|------------|-------------|-----|
| Healthy Smokers | 1 | 506 | 5612 | 1775 | 827 | 9.4 | 189 | 42 | F | nil | 15 | 93 |
| Healthy Smokers | 2 | 547 | 5740 | 4568 | 221 | 15 | 304 | 42 | F | nil | 22 | 92 |
| Healthy Smokers | 3 | 376 | 4830 | 4310 | 796 | 17.5 | 246 | 38 | F | nil | 10 | 98 |
| Healthy Smokers | 4 | 463 | 5590 | 2609 | 716 | 4.4 | 593 | 35 | F | nil | 15 | 100 |
| Healthy Smokers | 5 | 446 | 5103 | - | 544 | - | - | 48 | F | nil | 20 | 90 |
| Healthy Smokers | 6 | 837 | 4733 | 878 | 461 | 16 | 55 | 26 | F | nil | 10 | 101 |
| Healthy Smokers | 7 | 1671 | 2761 | 780 | 3362 | 3.5 | 223 | 24 | F | nil | 11 | 105 |
| Healthy Smokers | 8 | 697 | 4856 | 1956 | 673 | 7 | 279 | 33 | F | nil | 15 | 98 |
| Healthy Smokers | 9 | 368 | 5585 | 1684 | 393 | 12.8 | 132 | 28 | M | nil | 10 | 109 |
| Healthy Smokers | 10 | 403 | 3431 | 9558 | 425 | 12.7 | 753 | 38 | F | nil | 20 | 93 |
| Mean values of Patient Group | | 516 | 4824 | 3270 | 562 | 11.4 | 312 | 35 | 1 M | - | 14.8 | 98 |

| Patient Group | Mean [sE-cadherin] in sputum supernatant (ng/ml) | Mean [sE-cadherin] in serum (ng/ml) | Mean [sE-cadherin] in urine (ng/ml) | Mean [IL-8] | Mean [Creatinine] (mmol/L) | [Urine]/[Creatinine] ratio | Age of patient | Sex of patient | Medication taken by patient | Pack Years | FEV1 % pred |
|------------------------------|--|-------------------------------------|-------------------------------------|-------------|----------------------------|----------------------------|----------------|----------------|-----------------------------|------------|-------------|
| Healthy Non-Smokers | 1 | 673 | 5951 | 842 | 704 | 7.4 | 114 | 28 | F | nil | 101 |
| Healthy Non-Smokers | 2 | 1006 | 7463 | 3976 | 179 | 15 | 265 | 41 | F | nil | 96 |
| Healthy Non-Smokers | 3 | 654 | 2617 | 750 | 547 | 3 | 250 | 28 | F | nil | 99.4 |
| Healthy Non-Smokers | 4 | 538 | 4697 | 2737 | 603 | 8 | 342 | 31 | F | nil | 97 |
| Healthy Non-Smokers | 5 | 1118 | 6804 | 4022 | 206 | 17.3 | 232 | 33 | F | nil | 83 |
| Healthy Non-Smokers | 6 | 367 | 3544 | 3329 | 337 | 11.2 | 297 | 21 | F | nil | 104 |
| Healthy Non-Smokers | 7 | 782 | 8697 | 4639 | 667 | 12.4 | 374 | 52 | F | nil | 100 |
| Healthy Non-Smokers | 8 | 673 | 7357 | 4918 | 347 | 11.5 | 428 | 47 | F | nil | 95 |
| Healthy Non-Smokers | 9 | 976 | 4041 | 4963 | 683 | 8.5 | 584 | 43 | F | nil | 84 |
| Healthy Non-Smokers | 10 | 1375 | 6094 | 2199 | 584 | 20 | 110 | 28 | F | nil | 99.4 |
| Mean values of Patient Group | | 816 | 5726 | 3237 | 486 | 11.4 | 300 | 35 | 0 M | - | 95.9 |

| Patient Group | Mean [sE-cadherin] in sputum supernatant (ng/ml) | Mean [sE-cadherin] in serum (ng/ml) | Mean [sE-cadherin] in urine (ng/ml) | Mean [IL-8] | Mean [Creatinine] (mmol/L) | [Urine]/[Creatinine] ratio | Age of patient | Sex of patient | Medication taken by patient | Pack Years | FEV1 % pred |
|------------------------------|--|-------------------------------------|-------------------------------------|-------------|----------------------------|----------------------------|----------------|----------------|-----------------------------|------------|-------------|
| Asthma | 1 | 334 | 5041 | 4900 | 753 | 13.7 | 358 | M | salb | nil | 101 |
| Asthma | 2 | 508 | 2027 | 3464 | 48 | 23 | 151 | M | salb | nil | 98 |
| Asthma | 3 | 240 | 6153 | 1817 | 73 | 7.1 | 256 | F | salb | nil | 89 |
| Asthma | 4 | 348 | 4168 | 1190 | 37 | 4.1 | 290 | F | salb | nil | 95 |
| Asthma | 5 | 577 | 5403 | 2228 | 528 | 10.3 | 216 | M | salb | nil | 94 |
| Asthma | 6 | 584 | 4625 | 4003 | 539 | 11 | 364 | M | salb | nil | 92 |
| Asthma | 7 | 320 | 5101 | 3406 | 285 | 16.7 | 204 | F | salb | nil | 84 |
| Asthma | 8 | 324 | 6190 | 320 | 496 | - | - | F | salb | nil | 98 |
| Asthma | 9 | 1767 | 4044 | 8039 | 2070 | 6.4 | 1256 | M | salb | nil | 89 |
| Asthma | 10 | 693 | 6038 | 2034 | 125 | 8.5 | 239 | F | salb | Nil | 98 |
| Mean values of Patient Group | | 436 | 4879 | 3140 | 320 | 11.2 | 370 | 32 | 5 M | - | 94 |

FIG. 1
Soluble E Cadherin in Serum Samples from 4 Patient Groups




FIG. 2

Soluble E Cadherin in Urine samples from 4 Patient Groups

